Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Welsh regulator backs limited access to leukaemia drug

NHS patients in Wales should have access to a new treatment for chronic myeloid leukaemia (CML), according to the All Wales Medicines Strategy Group.Dasatinib (Sprycel) has been recommended for the treatment of adults with chronic or accelerated phase CML, where there is resistance or intolerance to prior therapy including imatinib mesylate. The drug is an oral tyrosine kinase inhibitor that blocks leukaemia cell growth, enabling adults with certain types of the CML ...

Subscribe for full online access and get...

  • Full, instant access to all stories
  • Customised email alerts straight to your inbox
  • 5,000+ practice articles in our clinical archive
  • Online learning units on fundamental aspects of nursing care

Register for guest access to keep reading and get...

  • A free taste of other selected news stories
  • Daily email newsletters

Speak with a member of the team about providing Nursing Times for your whole team
Are you a student nurse? Take advantage of a discounted rate by clicking here (Graduation date required)
Already have an account? Sign in